Results 111 to 120 of about 19,502 (213)

A new approach to assessing the efficacy of anthelmintic agents in vitro

Бюллетень сибирской медицины
Aim. To develop a new method to determine the viability of Opisthorchis felineus in vitro using the MTS reagent and to evaluate its applicability for analyzing the efficacy of anthelmintic agents in the treatment of opisthorchiasis.Materials and methods.
E. A. Perina, E. E. Buyko, I. P. Kaminskiy, D. S. Sobakin, A. A. Ufandeev, O. A. Kaidash, V. V. Ivanov, E. V. Udut   +7 more
doaj   +1 more source

Praziquantel and clonorchiasis [PDF]

Antimicrobial Agents and Chemotherapy, 1987
A C, Lin, S W, Chapman
openaire   +2 more sources

Adverse event incidence, praziquantel 40 mg/kg.

, 2014
Legend. ci, confidence interval.Adverse event incidence, praziquantel 40 mg/kg.
Piero L. Olliaro (217564), Julien Zwang (261429)   +1 more
core   +1 more source

Schistosomiasis Chemotherapy, Chemoprevention, and Vaccines: History, Progress, and Priorities

Immunity, Inflammation and Disease
Background Schistosomiasis is a major human disease of public health importance. Freshwater snails serving as intermediary hosts and human interaction with surface water tainted by feces or urine are both necessary components of the transmission cycle ...
Alaa Oqalaa E. Alibrahim, Walaa A. Elkholy, Mona M. El‐Derbawy, Noha F. Zahran, Athanasios Alexiou, Marios Papadakis, Gaber El‐Saber Batiha   +6 more
doaj   +1 more source

[Progress of Research on Preparation and Application of Praziquantel]

, 2013
Praziquantel remains the drug of choice for schistosomiasis, but it has the low bioavailability and single dosage form. This paper reviews the properties of praziquantel in vivo and in vitro, the pathogenic characteristics of schistosomiasis, and the ...
Ma, Zheng, Wu, De-Zhi, Liu, Yun-Feng, Zhu, Wei-Feng, Ning, An   +4 more
core  

Effect of praziquantel treatment.

, 2014
Figures comparing FGS positive individuals in blood (A–B) and cervical samples (C–D) before and after praziquantel (40 mg/kg) treatment.
Mathias Onsrud (238182), Sigve D. Holmen (572468), Elisabeth Kleppa (392587), Myra Taylor (392589), Veron Ramsuran (572463), Siphosenkosi Zulu (572464), Alfred Bere (509668), Svein Gunnar Gundersen (218565), Thumbi Ndung’u (159362), Gunn Hege Karlsen (572465), Patricia Ndhlovu (572466), Kristine Lillebø (572467), Jo-Ann S. Passmore (509669), Eyrun F. Kjetland (372597)   +13 more
core   +1 more source

Interactions of mefloquine with praziquantel in the Schistosoma mansoni mouse model and in vitro

, 2011
Objectives Mefloquine has interesting antischistosomal properties, hence it might be an attractive partner drug for combination treatment with praziquantel.
T. Manneck, Manneck, T., Vargas, M., Keiser, J., J. Keiser, M. Vargas   +5 more
core   +1 more source

Cucurbita pepo Seed Oil Induces Microsatellite Instability and Tegumental Damage to Schistosoma mansoni Immature and Adult Worms In vitro

Infection and Drug Resistance, 2020
Amany Ibrahim Ammar, 1 Amira Fathy Afifi, 1 Abdallah Essa, 2, 3 Asmaa Galal-Khallaf, 4 Mostafa Mohamed Mokhtar, 5 Somaia Shehab-Eldeen, 2, 3 Amany Ahmed Rady 1 1Department of Medical Parasitology, Faculty of Medicine, Menoufia University, Shebin El Kom,
Ammar AI, Afifi AF, Essa A, Galal-Khallaf A, Mokhtar MM, Shehab-Eldeen S, Rady AA   +6 more
doaj  

A novel sustained-release agent based on disulfide-induced recombinant collagen hydrogels for the prevention and treatment of Schistosoma infections

Microbiology Spectrum
Schistosomiasis is commonly managed using the praziquantel, but it is only effective against adult worms and duration of action is short. Liver fibrosis will worsen if eggs are still present after stopping treatment.
Jie Wang, Lijun Song, Yuntian Xing, Yang Dai, Jinyuan Hu, Guoli Qu, Yongliang Xu, Xuren Yin, Derong Hang, Jianfeng Zhang, Chunrong Xiong, Liang Shi, Fei Xu   +12 more
doaj   +1 more source

Praziquantel pharmacokinetics and side effects in Schistosoma japonicum-infected patients with liver disease.

, 1988
Praziquantel undergoes extensive first-pass hepatic biotransformation, but there is little information on its disposition or toxicity when administered to patients with liver disease.
L. Padre, C. P. Ranoa, G. Watt, W. Ritter, L. W. Laughlin, M. T. Fernando, N. J. White   +6 more
core   +1 more source